Miv-cel Manufacturing Secured
Kyverna Secures Five-Year Manufacturing Partnership with ElevateBio for Miv-cel Supply
Anonymous
Key Points
1
The five-year ElevateBio deal includes minimum purchase commitments and inflation-linked pricing for miv-cel manufacturing.
2
The arrangement formalizes a three-year collaboration that supported Kyverna’s SPS biologics license application (BLA) and commercialization planning.
3
ElevateBio is described as a CDMO with high clinical success rates for miv-cel, reinforcing confidence in scalable, reliable manufacturing.
4
Kyverna displays strong near-term liquidity with a current ratio of 8.15, indicating substantial short-term financial strength relative to liabilities.
5
The company’s market data show a market capitalization around $451 million with the stock trading near $7.42 and a 52-week high of $13.67, signaling potential upside but notable volatility.
Kyverna Therapeutics has signed a five-year manufacturing and commercial supply deal with ElevateBio for miv-cel, its lead CAR-T cell therapy, according to TipRanks. The agreement replaces a 2023 pact and locks in scalable, long-term manufacturing capacity for both U.S. commercial launch and global clinical trials.
Shares of Kyverna rose on the news, Benzinga reported. The deal positions the company for potential market entry in stiff person syndrome and generalized myasthenia gravis — two serious autoimmune diseases with few treatment options.
Five-Year Deal Replaces Earlier 2023 Manufacturing Pact
The new agreement formalizes a three-year working relationship between the two companies, according to TipRanks. That earlier collaboration already supported Kyverna's regulatory filings and commercialization planning. The new five-year term gives Kyverna a much longer runway to prepare for a full commercial launch.
The deal includes minimum purchase commitments and inflation-linked pricing, Contract Pharma reported. Those terms lock in predictable costs for Kyverna while guaranteeing ElevateBio a steady volume of orders. Kyverna is targeting a rolling Biologics License Application — a step-by-step FDA submission — for miv-cel by the end of 2026.
ElevateBio Brings High Clinical Success Rates to CAR-T Supply
ElevateBio is a contract drug manufacturer, or CDMO, that specializes in cell and gene therapies. GuruFocus noted that the company brings high clinical success rates for miv-cel manufacturing. That track record matters because CAR-T therapies are complex to make — they are built from each patient's own cells.
Miv-cel targets CD19, a protein found on immune cells that drive autoimmune diseases. By pairing with ElevateBio, Kyverna aims to streamline its supply chain and reduce the risk of manufacturing delays ahead of a potential FDA approval, according to GuruFocus.
Kyverna's Finances Show Strong Liquidity but No Revenue Yet
Kyverna is still pre-revenue, with ongoing cash burn from clinical trials and regulatory work. But its current ratio stands at 8.15, meaning it has more than eight dollars of short-term assets for every dollar of short-term debt. That signals strong near-term financial health, according to TipRanks.
The company's market cap sits at roughly $451 million. Its stock trades near $7.42, well below a 52-week high of $13.67, according to Benzinga. That gap shows meaningful volatility but also potential upside if clinical milestones hit on schedule.
Analysts See Upside as Autoimmune Cell Therapy Race Heats Up
Analysts have placed a Buy rating on Kyverna stock with a price target near $25, according to TipRanks. That target is more than three times the current share price. Investor optimism is driven by the company's late-stage pipeline and its extended cash access secured through prior fundraising.
The autoimmune CAR-T space is competitive, but Kyverna's focus on stiff person syndrome and generalized myasthenia gravis gives it defined target markets. The ElevateBio partnership, Contract Pharma noted, is designed to make sure manufacturing does not become a bottleneck on the road to approval.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
13
Reach
23
Topics
A
AnonymousAuthor
